Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2023-10-31 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于子公司全人源抗破伤风毒素单克隆抗体A82/B86注射液组合制剂临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High-tech Industry Group Co., Ltd. regarding the approval of a clinical trial application for a monoclonal antibody injection by its subsidiary. It includes details about the drug, regulatory approval from the National Medical Products Administration, and potential impacts and risks. The document is short (1241 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report but an announcement of a regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-10-31 Chinese
关于控股子公司外用人粒细胞巨噬细胞刺激因子凝胶补充申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High & New Technology Industries (Group) Co., Ltd. regarding the approval of a supplementary application for a product by its controlling subsidiary. It details the approval from the National Medical Products Administration (国家药品监督管理局) for changes in product usage instructions, storage conditions, and product description. The document is an announcement of regulatory approval related to product information, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed financial analysis. The document length is short (1226 characters) and it serves as a formal announcement of regulatory approval. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-10-30 Chinese
关于首次回购公司股份暨回购结果与股份变动的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Changchun High-tech Industry (Group) Co., Ltd. regarding the company's first share repurchase, including details of the repurchase results and changes in shareholding. It specifies the number of shares repurchased, the price range, total amount spent, compliance with regulatory rules, and the intended use of the repurchased shares for employee stock incentives. The document also confirms that the repurchase plan has been fully implemented and provides information on the impact of the repurchase on the company's share structure. This is a clear report of the company buying back its own shares, which fits the definition of a Transaction in Own Shares (POS) filing. The document length is under 5,000 characters but contains detailed data about the repurchase, not just an announcement of a report publication, so it is not an RPA. Therefore, the correct classification is POS with high confidence.
2023-10-29 Chinese
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2023 Third Quarter Report" of 长春高新技术产业（集团）股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes on financial performance for the third quarter of 2023. The document explicitly states it is a quarterly report and is unaudited. The length of the document (over 12,000 characters) and the presence of comprehensive financial statements confirm it is a substantive interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-10-23 Chinese
关于子公司投资建设项目的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (865 characters) from Changchun High-tech Industry Group Co., Ltd. regarding an investment project by its subsidiary to build a vaccine production facility. It includes details about the project, investment amount, and expected impact on future performance. There is no financial data, no regulatory form references, and no indication of a full report. The document is an investment project update, which fits best under Capital/Financing Update (CAP) as it relates to company investment activities and capital expenditure plans. The document is not a report publication announcement or regulatory filing, as it contains substantive information about the investment decision.
2023-10-23 Chinese
关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement regarding the progress of a share repurchase program by the company 长春高新技术产业（集团）股份有限公司. It details the board approval of the share buyback plan, the intended use of funds, the price limits, and the regulatory compliance for disclosure. It explicitly states that as of the end of September 2023, no shares have been repurchased yet, and that the company will continue to disclose progress updates. The document is not a financial report, earnings release, or management discussion, but a formal update on the company's share repurchase activity. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length and content confirm it is not merely an announcement of a report but an actual progress update on share repurchase.
2023-10-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.